ArticleNature2017
Zanos et al. reply.
Abstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders.Biological psychiatry · 2025Review
- The Emerging Role of Long Noncoding RNAs in Sorafenib Resistance Within Hepatocellular Carcinoma.Cancers · 2024Review
- The role of NMDARs in the anesthetic and antidepressant effects of ketamine.CNS neuroscience & therapeutics · 2024Review
- Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2ACS chemical neuroscience · 2022Article
- Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.Drug discovery today · 2021Review
- Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.Pharmacological reviews · 2021Review
- Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Review
- Ketamine: Neuroprotective or Neurotoxic?Frontiers in neuroscience · 2021Review
- (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- (Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Antidepressant-relevant concentrations of the ketamine metabolite (2Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Article
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.Pharmacological reviews · 2018Review
- Mechanisms of ketamine action as an antidepressant.Molecular psychiatry · 2018Review
- Convergent Mechanisms Underlying Rapid Antidepressant Action.CNS drugs · 2018Review
- Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.Psychopharmacology · 2018Review
- Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites.Organic letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Panos ZanosDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Ruin MoaddelBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.
Patrick J MorrisDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20892, USA.
Polymnia GeorgiouDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Jonathan FischellDepartment of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Greg I ElmerDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Manickavasagom AlkondonDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Peixiong YuanExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20814, USA.
Heather J PributDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Nagendra S SinghBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.
Katina S S DossouBiomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.
Yuhong FangDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20892, USA.
Xi-Ping HuangNIMH Psychoactive Drug Screening Program, Department of Pharmacology and Division of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill Medical School, Chapel Hill, North Carolina 27516, USA.
Cheryl L MayoMaryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA.
Edson X AlbuquerqueDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Scott M ThompsonDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20892, USA.
Carlos A ZarateExperimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20814, USA.
Todd D GouldDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Funding
Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0MDisease Status Drug Metabolism and New Drug Discovery ZIAAG000297 · NIA · NATIONAL INSTITUTE ON AGING · PI EGAN, JOSEPHINE · 2009 to 2025
$38.2MTarget validation of novel therapeutic agents in mood disordersZIAMH002927 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2010 to 2025
$37.1MTherapeutic Efficacy of Ketamine Metabolites for Depression TreatmentR01MH107615 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI GOULD, TODD D · 2016 to 2025
$7.2MStress, Depression, Serotonin, and Plasticity of Excitatory TransmissionR01MH086828 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI THOMPSON, SCOTT M. · 2010 to 2019
$3.8MIntramural NIH HHS ZIA MH002857NIMH NIH HHS R01 MH086828NIMH NIH HHS R01 MH107615
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.